Trials · 2014
Forced diuresis with matched hydration in reducing acute kidney injury during transcatheter aortic valve implantation (Reduce-AKI): study protocol for a randomized sham-controlled trial.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Arbel Yaron, Ben-Assa Eyal, Halkin Amir, Keren Gad, Schwartz Arie Lorin, Havakuk Ofer, Leshem-Rubinow Eran, Konigstein Maayan, Steinvil Arie, Abramowitz Yigal, Finkelstein Ariel, Banai Shmuel
Аннотация
BACKGROUND: Acute kidney injury (AKI) is observed in up to 41% of patients undergoing transcatheter aortic valve implantation (TAVI) and is associated with increased risk for mortality. The aim of the present study is to evaluate whether furosemide-induced diuresis with matched isotonic intravenous hydration using the RenalGuard system reduces AKI in patients undergoing TAVI.
METHODS/DESIGN: Reduce-AKI is a randomized sham-controlled study designed to examine the effect of an automated matched hydration system in the prevention of AKI in patients undergoing TAVI. Patients will be randomized in a 1:1 fashion to the RenalGuard system (active group) versus non-matched saline infusion (sham-controlled group). Both arms receive standard overnight saline infusion and N-acetyl cysteine before the procedure.
DISCUSSION: The Reduce-AKI trial will investigate whether the use of automated forced diuresis with matched saline infusion is an effective therapeutic tool to reduce the occurrence of AKI in patients undergoing TAVI.
TRIAL REGISTRATION: Clinicaltrials.gov: NCT01866800, 30 April 30 2013.
METHODS/DESIGN: Reduce-AKI is a randomized sham-controlled study designed to examine the effect of an automated matched hydration system in the prevention of AKI in patients undergoing TAVI. Patients will be randomized in a 1:1 fashion to the RenalGuard system (active group) versus non-matched saline infusion (sham-controlled group). Both arms receive standard overnight saline infusion and N-acetyl cysteine before the procedure.
DISCUSSION: The Reduce-AKI trial will investigate whether the use of automated forced diuresis with matched saline infusion is an effective therapeutic tool to reduce the occurrence of AKI in patients undergoing TAVI.
TRIAL REGISTRATION: Clinicaltrials.gov: NCT01866800, 30 April 30 2013.
Предметные рубрики MeSH
AcetylcysteineAcute Kidney InjuryAntioxidantsCardiac CatheterizationClinical ProtocolsContrast MediaCoronary AngiographyDiuresisDiureticsDouble-Blind MethodDrug Administration ScheduleFluid TherapyFurosemideHeart Valve Prosthesis ImplantationHumansInfusions, IntravenousIsraelResearch DesignSodium ChlorideTime FactorsTreatment OutcomeUrinary Catheterization